JP6755256B2 - 骨折リスクの低減におけるＰＴＨｒＰアナログの使用 - Google Patents

骨折リスクの低減におけるＰＴＨｒＰアナログの使用 Download PDF

Info

Publication number
JP6755256B2
JP6755256B2 JP2017546245A JP2017546245A JP6755256B2 JP 6755256 B2 JP6755256 B2 JP 6755256B2 JP 2017546245 A JP2017546245 A JP 2017546245A JP 2017546245 A JP2017546245 A JP 2017546245A JP 6755256 B2 JP6755256 B2 JP 6755256B2
Authority
JP
Japan
Prior art keywords
avaloparatide
bmd
bone
treated
teriparatide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017546245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508530A5 (https=
JP2018508530A (ja
Inventor
ハタスリー，ガリー
Original Assignee
ラジウス ヘルス，インコーポレイテッド
ラジウス ヘルス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56849024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6755256(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ラジウス ヘルス，インコーポレイテッド, ラジウス ヘルス，インコーポレイテッド filed Critical ラジウス ヘルス，インコーポレイテッド
Publication of JP2018508530A publication Critical patent/JP2018508530A/ja
Publication of JP2018508530A5 publication Critical patent/JP2018508530A5/ja
Application granted granted Critical
Publication of JP6755256B2 publication Critical patent/JP6755256B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2017546245A 2015-03-03 2016-03-03 骨折リスクの低減におけるＰＴＨｒＰアナログの使用 Active JP6755256B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562127729P 2015-03-03 2015-03-03
US62/127,729 2015-03-03
US201562165841P 2015-05-22 2015-05-22
US62/165,841 2015-05-22
US201562201564P 2015-08-05 2015-08-05
US62/201,564 2015-08-05
US201562239733P 2015-10-09 2015-10-09
US62/239,733 2015-10-09
US201662278762P 2016-01-14 2016-01-14
US62/278,762 2016-01-14
PCT/US2016/020787 WO2016141250A1 (en) 2015-03-03 2016-03-03 USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020141522A Division JP7049412B2 (ja) 2015-03-03 2020-08-25 骨折リスクの低減におけるＰＴＨｒＰアナログの使用

Publications (3)

Publication Number Publication Date
JP2018508530A JP2018508530A (ja) 2018-03-29
JP2018508530A5 JP2018508530A5 (https=) 2019-04-11
JP6755256B2 true JP6755256B2 (ja) 2020-09-16

Family

ID=56849024

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017546245A Active JP6755256B2 (ja) 2015-03-03 2016-03-03 骨折リスクの低減におけるＰＴＨｒＰアナログの使用
JP2020141522A Active JP7049412B2 (ja) 2015-03-03 2020-08-25 骨折リスクの低減におけるＰＴＨｒＰアナログの使用
JP2022050196A Pending JP2022075999A (ja) 2015-03-03 2022-03-25 骨折リスクの低減におけるＰＴＨｒＰアナログの使用
JP2023117588A Pending JP2023129523A (ja) 2015-03-03 2023-07-19 骨折リスクの低減におけるＰＴＨｒＰアナログの使用
JP2025064970A Pending JP2025100689A (ja) 2015-03-03 2025-04-10 骨折リスクの低減におけるＰＴＨｒＰアナログの使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020141522A Active JP7049412B2 (ja) 2015-03-03 2020-08-25 骨折リスクの低減におけるＰＴＨｒＰアナログの使用
JP2022050196A Pending JP2022075999A (ja) 2015-03-03 2022-03-25 骨折リスクの低減におけるＰＴＨｒＰアナログの使用
JP2023117588A Pending JP2023129523A (ja) 2015-03-03 2023-07-19 骨折リスクの低減におけるＰＴＨｒＰアナログの使用
JP2025064970A Pending JP2025100689A (ja) 2015-03-03 2025-04-10 骨折リスクの低減におけるＰＴＨｒＰアナログの使用

Country Status (8)

Country Link
US (9) US20170065682A1 (https=)
EP (2) EP3265115B1 (https=)
JP (5) JP6755256B2 (https=)
AU (3) AU2016226103A1 (https=)
CA (1) CA2977812A1 (https=)
DK (1) DK3265115T3 (https=)
ES (1) ES2927067T3 (https=)
WO (1) WO2016141250A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10568937B2 (en) 2016-04-18 2020-02-25 Radius Health, Inc. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
CA3045458A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
WO2019232283A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
IL284533B2 (en) * 2019-01-11 2024-02-01 Radius Health Inc Methods for detecting antibodies to neutralizing thyroid hormone (PTH) and thyroid hormone-related peptide (PTHRP) analog
JP7454511B2 (ja) 2019-02-14 2024-03-22 富士フイルム株式会社 骨折リスク評価値取得装置及びその作動方法並びに骨折リスク評価値取得プログラム
EP4027899A4 (en) * 2019-09-12 2023-08-16 Radius Health, Inc. METHODS OF ENHANCING SPINE FUSION USING ABALOPARATIDE
CN112646042A (zh) * 2019-10-10 2021-04-13 陕西麦科奥特科技有限公司 活性多肽化合物
WO2022149066A1 (en) * 2021-01-05 2022-07-14 Radius Health, Inc. Treatment of long bone fractures with abaloparatide
US20220378881A1 (en) * 2021-05-25 2022-12-01 Radius Health, Inc. Treatment and prevention of osteoporosis in high body mass index individuals
WO2025032376A1 (en) * 2023-08-04 2025-02-13 Precise Biopharma Pvt Ltd A room temperature stable solution for injection of abaloparatide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
EP1531855A4 (en) * 2002-01-10 2009-07-22 Osteotrophin Llc TREATMENT OF BONE DISEASES WITH SKELETTAL ANABOLIKA
AU2006343306A1 (en) * 2005-09-06 2007-11-15 Zelos Therapeutics, Inc. Parathyroid hormone analogues and methods of use
HRP20120643T1 (hr) * 2006-08-25 2012-08-31 Ares Trading S.A. Liječenje poremećaja hrskavice sa fgf-18
BRPI0719821B8 (pt) * 2006-10-03 2021-05-25 Ipsen Pharma Sas composição estável na armazenagem apropriada para administração a pacientes
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
WO2010022176A1 (en) * 2008-08-19 2010-02-25 Ferring International Center S.A. Methods of treatment for skeletal conditons
EP2699252B1 (en) * 2011-04-22 2017-10-25 Radius Health, Inc. Method of drug delivery for pth, pthrp and related peptides
CN104619727B (zh) * 2012-06-25 2019-04-05 布里格姆及妇女医院股份有限公司 靶向治疗
KR20180067573A (ko) * 2015-10-09 2018-06-20 라디우스 헬쓰, 인코포레이티드 PTHrP 유사체의 제형, 이의 경피 패취, 및 이의 용도

Also Published As

Publication number Publication date
CA2977812A1 (en) 2016-09-09
EP4137147A2 (en) 2023-02-22
EP3265115A4 (en) 2019-05-22
EP4137147A3 (en) 2023-04-05
US20170065682A1 (en) 2017-03-09
JP2020189884A (ja) 2020-11-26
EP3265115A1 (en) 2018-01-10
WO2016141250A1 (en) 2016-09-09
JP2018508530A (ja) 2018-03-29
US20230381283A1 (en) 2023-11-30
AU2024202952A1 (en) 2024-05-23
AU2016226103A1 (en) 2017-08-31
JP2025100689A (ja) 2025-07-03
US20200061160A1 (en) 2020-02-27
US20200376088A1 (en) 2020-12-03
ES2927067T3 (es) 2022-11-02
US20220125887A1 (en) 2022-04-28
JP7049412B2 (ja) 2022-04-06
JP2022075999A (ja) 2022-05-18
US20230321199A1 (en) 2023-10-12
US20250195619A1 (en) 2025-06-19
JP2023129523A (ja) 2023-09-14
EP3265115B1 (en) 2022-06-22
US20170368148A1 (en) 2017-12-28
AU2020267182A1 (en) 2020-12-03
US20250387454A1 (en) 2025-12-25
DK3265115T3 (da) 2022-09-05

Similar Documents

Publication Publication Date Title
JP7049412B2 (ja) 骨折リスクの低減におけるＰＴＨｒＰアナログの使用
Cosman et al. Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial
Shah et al. Evaluation and management of osteoporosis and sarcopenia in patients with distal radius fractures
EA003362B1 (ru) Способ увеличения прочности и упругости кости и сокращения переломов
KR20210040171A (ko) 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
McClung et al. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss
CA2383574A1 (en) Method for reducing the risk of cancer
Cosman Teriparatide and abaloparatide treatment for osteoporosis
US20220378881A1 (en) Treatment and prevention of osteoporosis in high body mass index individuals
Ni et al. Comparative effect of eldecalcitol and alfacalcidol on bone microstructure: A preliminary report of secondary analysis of a prospective trial
HK40088026A (en) Uses of abaloparatide in reducing fracture risk
Mackie et al. Treatment of bone weakness in patients with femoral neck fracture by fluoride, calcium and vitamin D
Kobayakawa et al. Denosumab Versus Romosozumab for Postmenopausal Treatment
JP2026063324A (ja) 週２回の頻度でテリパラチド又はその塩を投与することを特徴とする、骨粗鬆症の予防又は治療方法
Famini et al. Hypercalcemia Secondary to Teriparatide in a Patient with Primary Hyperparathyroidism
DUAL-ENERGY et al. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2017): Poster Abstracts
WOMEN European Congress on Osteoporosis & Osteoarthritis
VITAMIN Eighth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis–ECCEO 8
Goss et al. Effects of Exemestane on Bone Strength in Postmenopausal Women at Increased risk for Developing Breast Cancer: A Companion Study to MAP. 3

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191224

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200323

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200727

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200825

R150 Certificate of patent or registration of utility model

Ref document number: 6755256

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250